Optimization of functional efficacy of phosphorothioate-modified oligonucleotides in a human CD8+ T-cell Ex Vivo expansion model

Scandinavian Journal of Immunology

Volumn 58, Issue 4, 2003, Pages 462-470

  Al Shanti, N A ^a   Steward, C G ^a,b   Garland, R J ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b Royal Hospital for Children   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; LIPOFECTIN; PHOSPHOROTHIOIC ACID;

ARTICLE; CHEMICAL MODIFICATION; EXPERIMENTAL MODEL; HUMAN; HUMAN CELL; LYMPHOCYTE CULTURE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE;

CD8-POSITIVE T-LYMPHOCYTES; CELL DIVISION; HUMANS; OLIGONUCLEOTIDES; OLIGONUCLEOTIDES, ANTISENSE; PROTEOGLYCANS;

EID: 0141482047     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3083.2003.01319.x     Document Type: Article

References (49)

1. + helper T cells recognizing class II alloantigens. J Immunol 1990;144:2425-35.
2. lo T lymphocytes control intracellular Brucella abortus infection as demonstrated in major histocompatibility complex class I- and class II-deficient mice. Eur J Immunol 1995;25:2551-7.
3. Sobao Y, Tomiyama S, Sugi K et al. The role of hepatitis B virus-specific memory CD8 T cells in the control of viral replication. J Hepatol 2002;36:105-15.
4. Riddell SR & Greenberg PD. Principles for adoptive T cell therapy of human viral diseases. Annu Rev Immunol 1995;13:545-86.
5. van der Bruggen P, Traversari C, Chomez P et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991;254:1643-7.
6. Hamann D, Baars PA, Rep MH et al. Phenotypic and functional separation of memory and effector human CD8+ T cells. J Exp Med 1997;186:1407-18.
7. Hamann D, Roos MT, van Lier RA. Faces and phases of human CD8 T cell development. Immunol Today 1999;20:177-80.
8. Stephenson ML & Zamecnik PC. Inhibition of Rous sarcoma virus RNA translation by a specific oligonucleotide. Proc Natl Acad Sci USA 1978;75:285-8.
9. Harel-Bellan A, Ferris DK, Vinocour M, Holt JT, Farrar W-L. Specific inhibition of c-myc protein biosynthesis using an antisense synthetic deoxy-oligonucleotide in human T lymphocytes. J Immunol 1988;140:2431-5.
10. Boeve CM & De Ley M. Inhibition of human interferon-gamma expressed by antisense oligodeoxynucleotides. J Leukoc Biol 1994;55:169-74.
11. Louie SW, Ramirez LM, Krieg AM, Maliszewski CR, Bishop GA. Endogenous secretion of IL-4 maintain growth and Thy-1 expression of a transformed B cell clone. J Immunol 1993;150:399-406.
12. Fujiwara T & Grimm EA. Specific inhibition of interleukin 1 beta gene expression by an antisense oligonucleotide: obligatory role of interleukin 1 in the generation of lymphokine-activated killer cells. Cancer Res 1992;52:4954-9.
13. Sierakowska H, Sambade MJ, Agrawal S, Kole R. Repair of thalassemic human beta-globin mRNA in mammalian cells by antisense oligonucleotides. Proc Natl Acad Sci USA 1996;93:12840-4.
14. Lisziewicz J, Sun D, Klotman M, Agrawal S, Zamecnik P, Gallo R. Specific inhibition of human immunodeficiency virus type 1 replication by antisense oligonucleotides: an in vitro model for treatment. Proc Natl Acad Sci USA 1992;89:11209-13.
15. Morelli S, Delia D, Capaccioli S et al. The antisense bcl-2-IgH transcript is an optimal target for synthetic oligonucleotides. Proc Natl Acad Sci USA 1997;94:8150-5.
16. Krieg AM, Gmelig-Meyling F, Gourley MF, Kisch WJ, Chrisey LA, Steinberg AD. Uptake of oligodeoxynucleotides by lymphoid cells is heterogeneous and inducible. Antisense Res Dev 1991;1:161-71.
17. Zhao Q, Matson S, Herrera CJ, Fisher E, Yu H, Krieg AM. Comparison of cellular binding and uptake of antisense phosphodiester, phosphorothioate, and mixed phosphorothioate and methylphosphonate oligonucleotides. Antisense Res Dev 1993;3:53-66.
18. Zhao Q, Song X, Waldschmidt T, Fisher E, Krieg AM. Oligonucleotide uptake in human hematopoietic cells is increased in leukemia and is related to cellular activation. Blood 1996;88:1788-95.
19. Kronenwett R, Steidl U, Kirsch M, Sczakiel G, Haas R. Oligodeoxynucleotide uptake in primary human hematopoietic cells is enhanced by cationic lipids and depends on the hematopoietic cell subset. Blood 1998;91:852-62.
20. Hartmann G, Krug A, Bidlingmaier M et al. Spontaneous and cationic lipid-mediated uptake of antisense oligonucleotides in human monocytes and lymphocytes. J Pharmacol Exp Ther 1998;285:920-8.
21. + cell population in normal healthy individuals and matched unrelated T-cells depleted bone marrow transplant recipients. Br J Haematol 2000;110:315-21.
22. + cytotoxic T lymphocytes. J Immunol Methods 1999;227:53-63.
23. Towbin H, Staehelin T, Gordon J. Electrophoresis transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 1979;76:4350-4.
24. Gao WY, Jaroszewski JW, Cohen JS, Cheng YC. Mechanisms of inhibition of herpes simplex virus type 2 growth by 28-mer phosphorothioate oligodeoxynucleotide. J Biol Chem 1990;265:20172-8.
25. Mislick KA & Baldeschwieler JD. Evidence for the role of proteoglycans in cation-mediated gene transfer. Proc Natl Acad Sci USA 1996;93:12349-54.
26. Ausubel FM, Brent R, Kingston RE, eds. Current Protocols in Molecular Biology. New York: Wiley, 1987, 17.13.17-32.
27. Yeoman LC, Danels YJ, Lynch MJ. Lipofectin enhance cellular uptake of antisense DNA while inhibiting tumor cell growth. Antisense Res Dev 1992;2:51-9.
28. Marti G, Egan W, Noguchi P, Zon G, Matsukura M, Broder S. Oligodeoxynucleotide phosphorothioate fluxes and localization in hematopoietic cells. Antisense Res Dev 1992;2:27-39.
29. Temsamani J, Kubert M, Tang J, Padmapriya A, Agrawal S. Cellular uptake of oligodeoxynucleotide phophorothioates and their analogs. Antisense Res Dev 1994;4:35-42.
30. Vlassov VV, Nechaeva MV, Karamyshev VN, Yakubov LA. Iontophoretic delivery of oligonucleotide derivatives into mouse tumor. Antisense Res Dev 1994;4:291-3.
31. Davies DE & Lloyd JB. Quantitation of pinocytosis in human monocytes during in vitro maturation into macrophages. J Immunol Methods 1990;132:111-7.
32. Swanson J, Bushnell A, Silverstein SC. Tubular lysosome morphology and distribution within macrophages depend on the integrity of cytoplasmic microtubules. Proc Natl Acad Sci USA 1987;84:1921-5.
33. Kooistra T & Lloyd JB. Tubular lysosome morphology and distribution within macrophages depends on the integrity of cytoplasmic microtubules. Int J Biochem 1985;17:805-11.
34. Brown DA, Kang SH, Gryaznov SM et al. Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding. J Biol Chem 1994;269:26801-5.
35. Wiedmann B, Sakai H, Davis TA, Wiedmann M. Comparative hybrid arrest by tandem antisense oligodeoxynucleotides or oligodeoxynucleoside methylphosphonates in a cell free system. Nature 1994;370:434-40.
36. Daaka Y & Wickstrom E. Target dependence of antisense oligodeoxynucleotide inhibition of c-Ha-ras p21 expression and focus formation in T24-transformed NIH3T3 cells. Oncogene Res 1990;5:267-75.
37. Stellrecht CM, Fraizer G, Selvanayagam C, Chao LY, Lee A, Saunders GF. Transcriptional regulation of the hematopoietic proteoglycan core protein gene during hematopoiesis. J Biol Chem 1993;268:4078-84.
38. Zabner J, Fasbender AJ, Moninger T, Poellinger KA, Welsh MJ. Cellular and molecular barriers to gene transfer by cationic lipid. J Biol Chem 1995;270:18997-9007.
39. - fractions. Immunology 1990;1319:7055-60.
40. Pinto L, Covas MJ, Victorino RM. Loss of CD45RA and gain of CD45RO after in vitro activation of lymphocytes from HIV-infected patients. Immunology 1991;73:147-50.
41. + T lymphocytes are enriched in antigen-specific T cells capable of down-modulating cytotoxic activity. Int Immunol 1998;10:311-23.
42. - precursors by differentiation occurring in late immune responses. Eur J Immunol 1994;24:1503-11.
43. Zhao Q, Waldschmidt T, Fisher E, Herrera CJ, Krieg AM. Stage specific oligonucleotide uptake in murine bone marrow B-cell precursors. Blood 1994;84:3660-6.
44. Akhtar S, Beck GF, Hawley P, Irwin WJ, Gibson I. The influence of polarized epithelial (Caco-2) cell differentiation on the cellular binding of phosphodiester and phosphorothioate oligonucleotides. Antisense Nucleic Acid Drug Dev 1996;6:197-206.
45. Hawley P & Gibson I. Interaction of oligodeoxynucleotides with mammalian cells. Antisense Nucleic Acid Drug Dev 1996;6:185-95.
46. Loke SL, Stein CA, Zhang XH et al. Characterization of oligonucleotide transport into living cells. Proc Natl Acad Sci USA 1989;86:3474-8.
47. Yakubov LA, Deeva EA, Zarytova VF et al. Mechanism of oligonucleotides uptake by cells: involvement of specific receptors? Proc Natl Acad Sci USA 1989;86:6454-8.
48. Benimetskaya L, Loike JD, Khaled Z et al. Mac-1 (CD11b/CD18) is an oligodeoxynucleotide-binding protein. Nat Med 1997;3:414-20.
49. Beltinger C, Saragovi HU, Smith RM et al. Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligonucleotides. J Clin Invest 1995;95:1814-23.